RA Capital Management Reports New 15.9% Stake in Inhibikase Therapeutics, Inc.

On July 17, 2026, RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., filed a Schedule 13G disclosing a new significant stake in Inhibikase Therapeutics, Inc. (IKT). The reporting persons acquired 25,000,000 shares of common stock, representing a 15.9% ownership interest in the company. This acquisition followed an at-the-market offering by the issuer that concluded on July 10, 2026. RA Capital Healthcare Fund, L.P. directly holds the shares, while RA Capital Management, L.P. serves as the investment adviser with delegated voting and dispositive power. Peter Kolchinsky and Rajeev Shah are identified as controlling persons of RA Capital's general partner. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This initial filing establishes RA Capital as a major institutional shareholder in Inhibikase Therapeutics.